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Indirect measures of cardiac vagal activity are strongly associated with exercise capacity, yet
a causal relationship has not been established. Here we show that in rats, genetic silencing of
the largest population of brainstem vagal preganglionic neurons residing in the brainstem’s
dorsal vagal motor nucleus dramatically impairs exercise capacity, while optogenetic
recruitment of the same neuronal population enhances cardiac contractility and prolongs
exercise endurance. These data provide direct experimental evidence that parasympathetic
vagal drive generated by a deﬁned CNS circuit determines the ability to exercise. Decreased
activity and/or gradual loss of the identiﬁed neuronal cell group provides a neurophysiological
basis for the progressive decline of exercise capacity with aging and in diverse disease states.
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E
lite endurance athletes display exceptionally high
parasympathetic vagal tone1,2. Although indirect measures
of high cardiac parasympathetic activity correlate with
enhanced exercise capacity3,4 and lower all-cause mortality5 in
athletes and the general population, it remains unclear (and
currently contentiously debated6,7) whether vagal tone can be
enhanced by exercise training. Alternatively, intrinsically high
parasympathetic activity, for example due to genetic factor(s),
could predispose some individuals to higher tolerance for
enduring training regimes, essential to achieve superior athletic
performance.
This study was designed to directly test the hypothesis that the
strength of vagal tone determines exercise capacity implying that
vagal withdrawal should reduce while vagal recruitment should
enhance the ability to exercise. We tested it in rodents by
genetically targeting the key population of vagal preganglionic
neurons that reside in the brainstem’s dorsal vagal motor nucleus
(DVMN). Developmental studies suggested that the DVMN is the
primary vagal nucleus and probably the most (evolutionary)
ancient central nervous system (CNS) structure which harbours
autonomic neurons in vertebrates8,9. Cardiac vagal preganglionic
neurons which reside in the DVMN innervate ventricular
myocardium10, but have limited control over the chronotropic
function9. These neurons are tonically active11 and critically
important for metabolic control12. A subset of DVMN neurons
provides functional innervation and contributes to the autonomic
control of the electrical and contractile properties of the left
ventricle (LV) of the heart13,14.
In this study, we show that genetic silencing of the DVMN
neurons dramatically impairs exercise capacity, while optogenetic
recruitment of this neuronal population enhances cardiac
contractility and prolongs exercise endurance in rats. These data
provide direct experimental evidence that parasympathetic drive
generated by the DVMN neurons determines the ability to
exercise.
Results
DVMN neuronal activity and the level of voluntary exercise.
First, electrophysiological recordings of DVMN neuronal activity
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Figure 1 | Activity of DVMN vagal preganglionic neurons determines
exercise capacity. (a) Left: mice were housed in standard home cages with
voluntary access to running wheels. Right: association between the intrinsic
activity of the DVMN neurons (recorded in brainstem slices in vitro) and the
amount of voluntary exercise exhibited by the animals in a 24 h period.
Inset: representative examples of the electrical activity of DVMN neurons
recorded in cell-attached conﬁguration in brainstem slices of mice which
were running 10 km (1) and 5.1 km (2) in a 24 h period. (b) Genetic
targeting of the DVMN vagal preganglionic neurons in rats.
Left: PRSx8-AlstR-IRES2-eGFP-LVV vector layout and schematic drawings of
the rat brain in saggital and coronal projections illustrating the anatomical
position of the DVMN, Right: photomicrograph of a representative coronal
section of the dorsal brainstem illustrating the distribution of transduced
DVMN neurons (eGFP ampliﬁed by immunohistochemistry) in the caudal
region of the nucleus (Bregma level:  13.8mm). Arrows point at ventrally
projecting axons of the transduced DVMN neurons (forming the efferent
vagus nerve). XII, hypoglossal motor nucleus (cells are not visible);
eGFP-IR, eGFP immunoreactivity; CC, central canal. Scale bar: 200mm.
(c) Summary data illustrating the effect of allatostatin (Alst) infusion into
the cisterna magna on exercise capacity in rats transduced to express eGFP
or AlstR/eGFP by the DVMN neurons. Data are presented as individual
values and means±s.e.m. Comparisons are made using ANOVA. (d) The
effect of allatostatin on exercise-induced changes in systemic arterial blood
pressure and heart rate in rats transduced to express eGFP or AlstR/eGFP
by the DVMN neurons. MAP, mean arterial blood pressure. Data are
presented as means±s.e.m. Comparisons are made using ANOVA. (e)
Summary data illustrating cardiac contractile responses (determined by
changes in the ﬁrst differential of left ventricular pressure, LVdP/dtmax) to b-
adrenoceptor stimulation (administration of dobutamine) at baseline
(paced at 20% above the resting heart rate) and after allatostatin infusion
into the cisterna magna in rats transduced to express eGFP or AlstR/eGFP
by the DVMN neurons. Data are presented as individual values and
means±s.e.m. Comparisons are made using paired t-test.
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were made in brainstem slices of adult mice that were housed in
standard home cages with voluntary access to the running wheels
(Fig. 1a). One hundred ﬁfteen DVMN neurons recorded in vitro
(that is, in the absence of afferent modulation from the periphery
and the rest of the CNS) from 14 mice exhibited a mean
spontaneous ﬁring rate of 1.46±0.12Hz. The mean DVMN
neuronal action potential ﬁring rate (determined for each mouse;
8 cells on average) in the range 0–1.7Hz increased with the
amount of voluntary exercise performed by the animals in a 24 h
period (Fig. 1a), supporting the hypothesis that intrinsic vagal
activity may determine the ability to exercise. This largely linear
relationship did not continue with spontaneous mean ﬁring rates
of DVMN neurons above 2Hz (recorded in brainstem slices of
two animals; Fig. 1a). Although, at present the reasons underlying
this biphasic relationship remain unclear, the lower amount of
voluntary exercise associated with a higher discharge rate of the
DVMN neurons could be potentially explained by negative ino-
tropic14 and chronotropic inﬂuences as well as non-cardiac effects
of high vagal activity. Considering that the majority of the vagal
projections originating from the DVMN innervate visceral
targets, it is conceivable that higher discharge rate of the
DVMN neurons mimics the post-prandial state and, thus, may
reduce the motivation to exercise. As voluntary exercise is
dependent on motivation, and motivation is determined by a
multitude of factors, the design of the subsequent studies
employed forced exercise experimental paradigm.
The effect of DVMN neuronal inhibition on exercise capacity.
Next, in rats, highly speciﬁc inhibition or recruitment of vagal
activity was achieved by targeting the DVMN neurons using viral
vectors to express either an inhibitory Gi-protein-coupled
Drosophila allatostatin receptor15 (AlstR; Fig. 1b) or light-sensitive
optogenetic actuator ChIEF16 (Fig. 2a). Insect peptide allatostatin
rapidly inhibits autonomic neurons transduced to express
AlstR17,18 while 445 nm light pulses trigger precisely timed
depolarizations and action potential ﬁring of DVMN neurons
expressing ChIEF18. Exercise capacity (expressed as work done in
Joules, J) was determined in an experimental paradigm employing
forced exercise on a single lane rodent treadmill following
selection for compliance and three 24-h spaced acclimatizing
training sessions. After the initial training period, rats expressing
AlstR and control transgene (enhanced green ﬂuorescent protein,
eGFP) achieved similar baseline exercise capacities (Fig. 1c).
Inhibition of the DVMN neurons expressing AlstR following
infusion of allatostatin into the cisterna magna dramatically
reduced the exercise capacity (from 1.40±0.15 to 0.26±0.08 kJ;
Po0.001; ANOVA; Fig. 1c). Exercise capacity fully recovered
within the next 24 h (1.52±0.15 versus 1.40±0.15 kJ at baseline;
P¼ 0.7; ANOVA; Fig. 1c). Peak increases in the arterial blood
pressure (ABP) and heart rate during exercise were blunted in
conditions of DVMN silencing (120±2 versus 135±7mmHg in
controls; P¼ 0.03; ANOVA and 510±7 versus 546±12 b.p.m. in
controls; P¼ 0.03; ANOVA, respectively; Fig. 1d). These data
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Figure 2 | Recruitment of vagal activity increases exercise capacity.
(a) Photomicrographs of coronal sections of the rat brainstem taken at low
(left) and high (right) magniﬁcation illustrating representative examples of
CHIEFtdTomato expression in the caudal region of the DVMN (Bregma
level:  13.8mm) 6 weeks after microinjections of PRSx8-ChIEFtdTomato-
LVV. Neurons display speciﬁc membrane localization of the transgene.
Arrows point at ventrally projecting axons of the transduced DVMN
neurons (forming the efferent vagus nerve). XII, hypoglossal motor nucleus;
NTS, nucleus of the solitary tract. Scale bars: 500mm (left), 200mm (right).
(b) Schematic drawing of the experimental setup. The rat brain drawn in
saggital projection shows the approximate positioning of the chronic
optrode implant. (c) Illustration of the experimental protocols. ChIEF,
animals transduced to express ChIEFtdTomato in the DVMN. eGFP, animals
transduced to express eGFP in the DVMN. (d) Exercise capacity of rats
transduced to express eGFP or ChiEFtdTomato by the DVMN neurons
before and after 4 days of light stimulation of the dorsal brainstem as well
as of a separate group of naive animals before and after 4 daily sessions of
treadmill exercise training. Data are presented as individual values and
means±s.e.m. Comparisons are made using ANOVA. (e) Summary data
showing LV ejection fraction at baseline and in response to b-adrenoceptor
stimulation (administration of dobutamine) in rats transduced to express
eGFP or ChiEFtdTomato by the DVMN neurons after 4 days of light
stimulation of the dorsal brainstem and in naive animals following four
daily sessions of exercise training. Data are presented as individual values
and means±s.e.m. Comparisons are made using ANOVA. (f) Left:
representative immunoblots showing GRK2 and b-arrestin 2 expression in
LV lysates of rats transduced to express eGFP or ChiEFtdTomato by the
DVMN neurons after 4 days of light stimulation of the dorsal brainstem.
Right: summary data illustrating means±s.e.m. of the densitometry of
GRK2 and b-arrestin 2 relative expression. *Po0.05 (ANOVA).
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suggested that vagal drive generated by the DVMN neurons is not
simply associated with, but determines the ability to exercise.
We next determined whether reduced activity of the DVMN
neurons may alter cardiac contractile responses to sympathetic
b-adrenoceptor-mediated stimulation, which is essential to
trigger and maintain appropriate increases in cardiac output to
support circulatory requirements of exercise. In anaesthetized
(urethane 1.3 g kg 1) rats expressing either eGFP or AlstR in the
DVMN neurons, systemic administration of the b1-adrenoceptor
agonist dobutamine (5 mg kg 1, intravenous (i.v.)) increased the
maximum differential of LV pressure (LVdP/dtmax; Fig. 1e) and
LV end systolic pressure (LVESP; Supplementary Fig. 1),
indicative of increased inotropy. Dobutamine had a similar effect
on LVdP/dtmax (increase by 700mmHg s 1; P¼ 0.03; paired t-
test; Fig. 1e) and LVESP (increase by 13mmHg; P¼ 0.006; paired
t-test; Supplementary Fig. 1) in rats expressing eGFP in the
DVMN following allatostatin infusion. However, when DVMN
neurons were silenced, b-adrenoceptor stimulation had no effect
on LVdP/dtmax (increase by 122mmHg s 1; P40.9; paired
t-test; Fig. 1e) and LVESP (increase by 1mmHg; P40.9; paired
t-test; Supplementary Fig. 1), suggesting that reduced vagal drive
from the DVMN impairs the ability of the heart to mount a
contractile response to sympathetic stimulation.
The effect of DVMN neuronal stimulation on exercise capacity.
In a reverse experimental paradigm, we determined whether
selective and highly speciﬁc optogenetic recruitment of the
DVMN activity (Fig. 2b) could increase exercise capacity. Rats
were selected on the basis of relatively poor baseline exercise
endurance and randomized into three experimental groups.
Exercise capacity was determined twice: on day 1 (baseline) and
on day 6 to determine the effect of treatment. During the 4 day
interim period (see timeline Fig. 2c), the dorsal brainstem of
rats expressing optogenetic actuator ChIEF (n¼ 9) or control
transgene eGFP (n¼ 10) in the DVMN neurons was illuminated
via an implanted optrode with 445 nm light (10ms, 15Hz)
for 15min/session (Fig. 2b). The third group of naive (non-
transduced) animals (n¼ 10) was subjected to daily sessions of
treadmill exercise training (B15min long). Four daily sessions of
vagal stimulation by optogenetic recruitment of the DVMN
activity was sufﬁcient to double the exercise capacity (0.94±0.11
versus 0.47±0.06 kJ in rats expressing eGFP; P¼ 0.002; ANOVA;
Fig. 2d, middle). This improvement in exercise capacity was
comparable to that observed in the naive rats trained to
exhaustion over the same time period (Fig. 2d, right). Ultrasound
assessment of LV function demonstrated that optogenetic DVMN
stimulation increased baseline ejection fraction (75±2% versus
62±1% in rats expressing eGFP; Po0.001; ANOVA; Fig. 2e) and
enhanced contractile response to b-adrenoceptor stimulation
with dobutamine (93±1 versus 84±2% in rats expressing eGFP;
P¼ 0.003; ANOVA; Fig. 2e). Resting heart rate and chronotropic
responses to dobutamine were similar between the experimental
groups (Supplementary Fig. 2).
Increased cardiac contractility (at rest and in response to
dobutamine challenge) following optogenetic stimulation of the
DVMN neurons suggested that the heart became more responsive
to sympathetic b-adrenoceptor stimulation. Western blot analysis
revealed that four daily sessions of vagal stimulation by
optogenetic recruitment of the DVMN activity resulted in a
signiﬁcant downregulation of left ventricular G-protein-coupled
receptor kinase 2 (GRK2) and b-arrestin 2 expression (Fig. 2f).
GRKs promote phosphorylation of the intracellular domains of
b-adrenoceptors, recruiting arrestins to block receptor couplling
to G-proteins resulting in receptor desensitization and
internalization19. These data suggest that the activity of the
DVMN neuronal projections has a major impact on LV inotropic
state by controlling expression of key negative regulators of
b-adrenoceptor-mediated signalling.
Cardiac vagal activity and aerobic capacity in humans. The data
obtained in rodents suggested that vagal drive powerfully
modulates cardiac reactivity to catecholamines and determines
exercise capacity. To investigate whether these conclusions are
consistent with the determinants of human exercise performance,
we next examined whether cardiac vagal activity correlates
with aerobic capacity in humans. Although the strength of
parasympathetic tone to the LV in humans is impossible to
measure directly, the rate of heart rate recovery (HRR) after
cessation of the exhaustive exercise serves as a robust index of
individual ability to recruit vagal tone (Fig. 3a) and is highly
sensitive to muscarinic blockade20. Assessment of HRR avoids
deriving parasympathetic activity from measures dependent on
absolute heart rate—a major confounder in heart rate variability
analysis21. We determined HRR in 1293 human participants
within an age range associated with the onset of vagal dysfunction
(63±14 years of age; BMI: 26.9±5.3; 67.5% males). We found a
graded relationship between HRR and independent measures of
aerobic performance including peak oxygen delivery (Fig. 3b),
anaerobic threshold (AT; Fig. 3c), predicted work rate (Fig. 3d),
VE=VCO2 (inversely related to cardiac output at peak exercise
22;
Supplementary Fig. 3) and oxygen pulse (Supplementary
Fig. 3),—a robust surrogate for LV stroke volume.
Discussion
Exercise capacity ultimately determines individual ability to chase
prey, escape from predators, explore new environments or simply
enjoy physical activity. The human exercise performance data and
the results of experimental animal studies reported here provide
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the ﬁrst direct evidence that the strength of the parasympathetic
vagal drive determines cardiac contractility and exercise capacity.
Differences in individual ability to exercise may, therefore, reﬂect
varying activity levels of the DVMN neuronal projections. We
hypothesize that high parasympathetic activity generated by the
DVMN neurons maintains the ability of the heart to mount an
augmented contractile response to sympathetic stimulation and
increases the ‘operational range’ of the heart by downregulating
GRK2 and arrestin expression in ventricular myocytes. This tonic
vagal inﬂuence originating from the DVMN appears to be
independent of relatively modest direct acetylcholine-mediated
negative inotropic effect14 and chronotropic control of the
heart, which is provided by another notable group of vagal
preganglionic neurons residing in the nucleus ambiguus9. Vagal
preganglionic neurons that innervate the LV are located in the
caudal region of the left DVMN14. Since DVMN neurons provide
parasympathetic innervation of the respiratory system and
various visceral organs, in order to preferentially recruit DVMN
cardiac projections we targeted the caudal aspects of the nucleus.
Although, DVMN inhibition or activation resulted in functional
and transcriptional changes at the level of the myocardium, it is
plausible that some of the observed changes in cardiac physiology
might be due to the inhibition/recruitment of vagal efferent
projections to other targets23 and recruitment of circulating
cardiotropic factor(s)24.
Higher parasympathetic vagal tone in elite athletes is suggested
to confer higher tolerance for intense exercise regimes and
might be further enhanced by unconventional stimuli, including
peripheral sensory (nociceptive) stimulation. For example,
cycle(s) of ischaemia/reperfusion applied to the limb appear to
recruit DVMN activity (as shown in an animal study18), increase
cardiac vagal activity in healthy volunteers25, and improve
exercise performance in highly trained athletes26. An ability to
respond to noxious stimuli (usually associated with threat and/or
injury) with increased endurance seems to have a clear
evolutionary advantage. On the other hand, DVMN neurons
are known to be highly susceptible to metabolic stress11 and
their dysfunction is associated with a host of autonomic
abnormalities11,27,28. The data obtained in the present study
also suggest that loss of DVMN activity may play a critical role in
the progressive decline of cardiac contractility and exercise
capacity during aging and in disparate disease states.
Methods
All the experiments were performed in accordance with the European Commission
Directive 2010/63/EU (European Convention for the Protection of Vertebrate
Animals used for Experimental and Other Scientiﬁc Purposes) and the UK Home
Ofﬁce (Scientiﬁc Procedures) Act (1986) with project approval from the
Institutional Animal Care and Use Committee. The human study was approved by
the NRES Committee London (Camden & Islington; MREC: 12/LO/0453).
Recording the activity of the DVMN neurons in vitro. Coronal (200 mm)
brainstem slices were obtained from 4–6 months old male C57BL/6J mice
terminally anaesthetized with halothane. Brains were dissected in ice–cold low
[Naþ ] solution containing 200mM sucrose, 2.5mM KCl, 28mM NaHCO3,
1.25mM NaH2PO4, 3mM pyruvate, 7mM MgCl2, 0.5mM CaCl2 and 7mM
glucose (pH 7.4). After recovery at 34 C for 30min in a solution containing:
118mM NaCl, 3mM KCl, 25mM NaHCO3, 1.2mM NaH2PO4, 7mM MgCl2,
0.5mM CaCl2 and 2.5mM glucose (pH 7.4), slices were kept at 34 C in artiﬁcial
cerebrospinal ﬂuid (aCSF) containing 118mM NaCl, 3mM KCl, 25mM NaHCO3,
1mM MgCl2, 2mM CaCl2 and 10mM glucose saturated with 95% O2 and 5% CO2
(pH 7.4).
The recording pipettes (3–6MO) were pulled from thin-walled borosilicate
capillaries. Recordings were performed in a cell-attached conﬁguration using an
EPC-9 ampliﬁer and Pulse/Pulseﬁt software (Heka Elektronik, Lambrecht,
Germany). Electrodes were ﬁlled with 120mM K-gluconate, 5mM HEPES,
5mM BAPTA, 1mM NaCl, 1mM MgCl2, 1mM CaCl2 and 2mM K2ATP (pH 7.2).
Recordings were conducted in aCSF saturated with 95% O2 and 5% CO2 at
28–32 C. Currents were ﬁltered at 1 kHz and digitized at 3 kHz. The mean action
potential frequency was determined by taking the average frequency over a period
of 5min. Recordings were analysed using Strathclyde Electrophysiology Software
(WinEDR/WinWCP; University of Strathclyde).
Genetic targeting of the DVMN vagal preganglionic neurons. Vagal
preganglionic neurons of the DVMN express the transcriptional factor Phox2 and
were targeted to express AlstR, a chimeric channelrhodopsin variant ChIEF fused
with a ﬂuorescent protein tdTomato (ChIEFtdTomato), or eGFP (control) using
lentiviral vectors (LVV) under the control of a Phox2-activated promoter PRSx8
(ref. 29). Validation of the vectors speciﬁcity in transducing the DVMN neurons
has been described in detail previously18. Application of allatostatin produces
rapid, selective inhibition of the autonomic (including vagal preganglionic)
neurons expressing AlstR17,18. Pulses of 445 nm light trigger precisely timed
depolarizations and action potential ﬁring of the DVMN neurons transduced to
express ChIEFtdTomato18.
Young male Sprague–Dawley rats (50–60 g) were anaesthetized using a
combination of ketamine (60mg kg 1; intramuscular (i.m.)) and medetomidine
(250 mg kg 1; i.m.). Adequate depth of surgical anaesthesia was maintained and
conﬁrmed by the absence of a withdrawal response to a paw pinch. With the head
held within a stereotaxic frame and ﬁxed in prone position, lidocaine (2% solution)
was injected subcutaneously for pre-operative analgesia before a midline dorsal
neck incision was made to expose the dorsal surface of the brainstem. DVMN
neurons spanning the rostro-caudal extent of the left and right nuclei were targeted
with two microinjections on each side (0.25 ml at a rate of 0.05 ml min 1)
of a solution containing viral particles of PRSx8-AlstR-IRES2-eGFP-LVV or
PRSx8-eGFP-LVV. To avoid transfection of the dorsal group of A2 neurons,
microinjections were madeB0.1mm ventral to the DVMN, restricting diffusion of
viral particles to the neighbouring NTS whilst sparing hypoglossal motoneurons,
which do not express Phox2 (Figs 1b and 2a). Taking the calamus scriptorius as the
reference point, the microinjections were made at 0.5mm rostral, 0.6mm lateral,
0.8mm ventral and at 1.0mm rostral, 0.8mm lateral, 0.6mm ventral. For
optogenetic vagal stimulation, DVMN neurons were targeted using the same
approach but with one microinjection of PRSx8-ChIEFtdTomato-LVV on each
brainstem side using the caudal set of coordinates. Using atipamezole (1mg kg 1;
i.m.) for reversal of anaesthesia, rats were then placed on a regime of post-operative
analgesia involving administration of buprenorphine (0.05mg kg 1 d 1; s.c.) for
3 days and carprofen (4mg kg 1 d 1; intraperitoneal (i.p.)) for 5 days.
Cannula/optrode implantations. Three to four weeks after the microinjections of
viral vectors into the DVMN, the animals were anaesthetized using a combination
of ketamine (60mg kg 1; i.m.) and medetomidine (250 mg kg 1; i.m.) and either a
26-gauge guide injection cannula (Plastic Products; in animals expressing AlstR or
eGFP) or conically tipped optrode (Art Photonics; in animals expressing
ChiEFtdTomato or eGFP) was stereotaxically implanted to reach the dorsal aspect
of the cisterna magna. Two small screws were placed into the skull, and the implant
was secured in place with dental acrylic. The guide cannula was closed with a
dummy cannula that extended from the tip of the guide cannula by B0.2mm.
Anaesthesia was reversed with atipamezole (1mg kg 1; i.m.). Carprofen was given
for post-operative analgesia and the animals were allowed to recover for at least 7
days before the experiments. Rats were 300–350 g at the time of the main study.
Biotelemetry transmitter implantation. Biotelemetry was used to record
systemic ABP and heart rate in exercising animals. Rats were anaesthetized using a
combination of ketamine (60mg kg 1; i.m.) and medetomidine (250 mg kg 1;
i.m.) and a laparotomy was performed to expose the abdominal aorta. A catheter
connected to a telemetry pressure transducer (model TA11PA-C40, Data Science
International) was advanced centrally into the aorta and secured with Vetbond
(3M). The transmitter was secured to the abdominal wall and the incision was
closed by successive suturing of the abdominal muscle and skin layers. Anaesthesia
was reversed with atipamezole (1mg kg 1; i.m.); carprofen was given and the
animals were returned to their home cages where they were allowed to recover for
at least 7 days before the experiments.
Exercise model. The exercise capacity of rats was determined in a forced exercise
experimental paradigm using a single lane rodent treadmill (Panlab Harvard
Apparatus) with an electrical shock grid set to the minimum perceived threshold
(0.1mA). The animals were selected on the basis of their treadmill compliance and
exercise capacity and subjected to daily recruitment/training sessions involving
running speeds of 20–30 cm s 1 over a 5min period after 15min of acclimatiza-
tion to the treadmill environment. To determine the exercise capacity, treadmill
speed was raised from 20 cm s 1 in increments of 5 cm s 1 every 5min until the
animal’s hind limbs made contact with the grid four times within a two minute
period—the humanely deﬁned point of exhaustion. The distance covered by the
animal was recorded and exercise capacity expressed as work done in Joules.
Assessment of cardiac contractility. The animals were anaesthetized with
urethane (1.3 g 1 kg 1; i.p.; following induction with 4% isoﬂurane). Adequate
level of anaesthesia was ensured throughout the experiment by continuous mon-
itoring of heart rate, and the ABP stability as well as the absence of a withdrawal
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15097 ARTICLE
NATURE COMMUNICATIONS | 8:15097 | DOI: 10.1038/ncomms15097 | www.nature.com/naturecommunications 5
response to a paw pinch. With an animal in a supine position, the femoral artery
and both femoral veins were cannulated for the measurements of the systemic
ABP, ﬂuid infusion and administration of drugs. The trachea was cannulated and
the animal was allowed to free breathe a supplied gas mixture. Body temperature
was maintained with a servo-controlled heating pad at 37.0±0.5 C. Partial pres-
sures of O2 and CO2 as well as pH of the arterial blood were measured every hour
(RAPIDLab 348EX, Siemens). If required, oxygen was added to the respiratory gas
mixture to maintain blood oxygenation within the physiological range. A 2F Millar
pressure catheter (SPR-320NR, Millar Instruments) was advanced via the right
carotid artery and placed within the chamber of the LV allowing recordings of LV
pressure (LVP). Averaged waveforms of LVP and systemic ABP were used to derive
the LVESP and the mean arterial blood pressure (MAP). The maximum limit of the
ﬁrst differential of LV pressure (LVdP/dtmax) was derived from the LVP recording
as an index of inotropic function. Atrial pacing at 20% above the resting heart rate
was performed using a 1.6F octapolar electrophysiology catheter (EPR-802, Millar
Instruments) positioned in proximity to the right atrium via the jugular vein. Data
were recorded using a Power1401 interface and analysed off-line using Spike2
software (Cambridge Electronic Design).
In some of the experiments, echocardiographic assessment of LV function
was conducted using a Vevo 2100 high-resolution ultrasound system with an
MS250 13–24MHz linear array transducer (VisualSonics). Baseline LV ejection
fraction and heart rate (lead II ECG) were determined in rats kept under urethane
(1.3 g 1 kg 1; i.p.; following induction with 4% isoﬂurane) anaesthesia. Ejection
fraction was determined using a B-mode acquisition of a parasternal long-axis view
of the LV measuring the length of the ventricle during systole and diastole. Three
short-axis images perpendicular to this were acquired along the length of the LV to
segment the endocardial border. Simpson’s rule was applied to approximate the
changes in LV volume30.
Histology. At the end of the experiments, the rats were administered with an
overdose of pentobarbitone sodium (200mg kg 1, i.p.) and perfused through the
ascending aorta with 0.9% NaCl solution followed by 500ml of 4% phosphate-
buffered (0.1M, pH 7.4) paraformaldehyde; the brains were removed and stored in
the same ﬁxative overnight at 4 C. Following cryoprotection (30% sucrose) of the
isolated brainstem, a sequence of transverse slices (30mm) was cut to determine the
extent of AlstR/eGFP, ChiEFtdTomato or eGFP expression by the DVMN neurons.
Immunoblotting. LV tissue was excised, snap frozen in liquid nitrogen and stored
at  80 C. GRK2 and b-arrestin 2 were immunodetected in cell lysates (whole cell
fractions) using anti-GRK2 antibody (C-9; sc-13143; Santa Cruz; 1:1,000 dilution)
and anti-b-arrestin 2 antibody (C16D9, 3857; Cell Signalling Technology; 1:1,000
dilution). Proteins were electrophoretically separated in SDS-PAGE gels and
transferred to polyvinylidene diﬂuoride membranes (Amersham Biosciences).
After antibody labelling, detection was performed (ECL detection system,
Amersham Biosciences). Densitometry was used to calculate the level of expression
normalized to the expression of a-tubulin to control protein loading. Uncropped
images of the western blots are shown on Supplementary Fig. 4.
Experiment 1. To determine whether the level of voluntary exercise correlates
with the activity of the DVMN neurons, fourteen adult male C57BL/6J mice
(age 4–6 months; JAXt Stock Number 000664; Charles–River Laboratories) were
housed one per cage in a room maintained at a constant temperature of 22±1 C,
with a 12:12 h light–dark cycle (with lights onset at 0600 h). Drinking water and
Laboratory Rodent Chow were provided ad libitum. After 1 week of acclimatization
to the new housing facility (following delivery from the supplier), running wheels
(Vet-Tech Solutions) were installed in all the cages. Distances run by individual
mice were recorded. After 4–6 weeks of housing with voluntary access to the
running wheels, activities of the DVMN neurons (on average 8 per animal) were
recorded in vitro in acute brainstem slices.
Experiment 2. To determine the effect of DVMN silencing on exercise capacity,
rats transduced to express AlstR (n¼ 8) or eGFP (n¼ 8) by the DVMN neurons
were selected for their exercise compliance and underwent three daily recruitment/
training sessions. Following the initial training period, their exercise capacity was
determined over the following three days: on day 1 to determine baseline exercise
capacity; on day 2 to determine exercise capacity in conditions of DVMN silencing
(15min following delivery of allatostatin peptide [Ser-Arg-Pro-Tyr-Ser-Phe-Gly-
Leu-NH2; 4 ml of 100mM solution in aCSF] into the cisterna magna) or
sham-treatment (in rats expressing eGFP by the DVMN neurons); and on day 3 to
determine exercise capacity after the recovery from the experimental treatment.
Microinjections into the cisterna magna were performed via an internal injection
cannula connected to a PE-20 tubing attached to a 50 ml syringe (Hamilton) driven
by a micro-infusion pump (model Sp210iw, World Precision Instruments). In a
separate experiment, changes in the ABP and heart rate during and after the
exercise were determined in seven rats expressing AlstR and in ﬁve rats expressing
eGFP by the DVMN neurons following allatostatin administration. For the
assessment of myocardial contractility, rats transduced to express AlstR (n¼ 6) or
eGFP (n¼ 5) by the DVMN neurons were anaesthetized with urethane and
prepared as described above. After the surgical preparation, the animals were left to
stabilize for 15–30min. The heart was paced at 20% above the resting heart rate. To
determine the effect of DVMN inhibition on cardiac responses to b-adrenoceptor
stimulation, dobutamine was given intravenously (infusion 2.5 mg kg 1 min 1 i.v.;
for 2min at a rate of 0.1mlmin 1) before and 15min after allatostatin
administration into the cisterna magna (4 ml of 100mM solution).
Experiment 3. To determine the effect of optogenetic DVMN stimulation on
exercise capacity, rats were pre-selected on the basis of a relatively poor baseline
exercise capacity and randomized in three experimental groups. Exercise capacity
was determined at two time points: on day 1 (baseline) and on day 6 to determine
the effect of treatment. In the interim 4 days, dorsal brainstem of rats expressing
ChiEFtdTomato (n¼ 9) or eGFP (n¼ 10) by the DVMN neurons was illuminated
via an implanted optrode using 445 nm light (10ms, 15Hz) for 15min under
isoﬂurane sedation (1–1.5% isoﬂurane, 1:1 O2/air mixture). A group of naive
animals (n¼ 10) underwent 4 sessions of treadmill exercise training over four
consecutive days with each session lasting up to the deﬁned point of exhaustion. To
determine the effect of enhanced DVMN activity and exercise training on inotropic
response induced by b-adrenoceptor stimulation, LV ejection fraction and heart
rate were determined before and after dobutamine challenge.
Experiment 4. To conduct cardiopulmonary exercise testing (CPET), ethical
approval (MREC: 12/LO/0453) was obtained from the UK National Information
Governance Board and in accordance with the Declaration of Helsinki. Participants
were enrolled prospectively at the University College London Hospitals, UK
(December 2007–May 2014), referred by their clinical team for CPET as part of the
routine assessment of exercise capacity. Participants gave written consent to use
CPET data. Exclusion criteria for CPET were in accordance with the international
guidelines31. Patients with/without delayed HRR had similar cardiovascular, renal
and nutritional proﬁles (Supplementary Tables 1 and 2).
Blinded investigators carried out all exercise testing. Equipment was calibrated
before each test using standard reference gases. Subjects undertook CPET on an
electronic cycle ergometer (Zan, nSpire or Lode) to maximal tolerance, adhering to
the protocol illustrated in Fig. 3a. Continuous 12-lead ECG was recorded.
Continuous breath-by-breath gas exchange analysis was performed. All subjects
were instructed to continue cycling until symptom-limited fatigue. CPET data were
analysed blinded to HRR. AT was determined by two independent assessors
blinded to autonomic parameters and in accord with published guidelines using the
modiﬁed V-slope method and conﬁrmed by ventilatory equivalents for carbon
dioxide (VE=VCO2 ) and oxygen (VE=VO2 ; refs 32,33). Peak oxygen consumption
(VO2peak), oxygen pulse and VE=VCO2 were determined. VE=VCO2 is inversely
related to cardiac output at peak exercise22. Predicted values, which take into the
account age, gender, weight and height, were calculated for VO2peak(ref. 34) and
oxygen pulse35—a robust measure of LV stroke volume36,37. Percent-predicted
peak VO2 values (derived from the Wasserman/Hansen equations) provide superior
measures of these variables38. Vagal dysfunction was deﬁned from HRR at 1min
following the cessation of exercise. We binned HRR values in increments of 5 beats
min 1. A failure to decrease heart rate by Z12 beats min 1 in one minute after
the end of exercise was used as a cut-off value, since published data show a robust
association between HRR ofr12 beats min 1 and increased risk of cardiovascular
death39,40.
Data analysis. Recordings of the cardiovascular variables were analysed
using Spike2 software (Cambridge Electronic Design). Differences between the
experimental groups were assessed using GraphPad Prism 6 software. Comparisons
were made using two-way ANOVA (followed by post hoc Tukey–Kramer testing)
or Student’s paired or unpaired t-test, as appropriate. For the analysis of data
obtained in the human study, the variables were compared according to the HRR
bin using general linear models of analysis of variance (quantitative variables),
controlling for age as a covariate where CPET variables are not referenced to
population norms. Data are reported as individual values and means±s.e.m.
Differences with Po0.05 were considered to be signiﬁcant.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding authors upon request.
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